Literature DB >> 15345691

Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70.

Diego Albani1, Erika Peverelli, Raffaela Rametta, Sara Batelli, Lorenzo Veschini, Alessandro Negro, Gianluigi Forloni.   

Abstract

Alpha-synuclein (alpha-syn) is a 140-amino acid presinaptic protein whose mutations A30P and A53T have been linked to familiar Parkinson's disease (PD). Many data suggest that alpha-syn aggregation is the key event that triggers alpha-syn-mediated neurotoxicity. Nevertheless, other lines of evidence proposed a protective role of alpha-syn against oxidative stress (a major feature of PD), even if the exact mechanism of this protective action and the role of the pathogenetic mutations to this respect have not been elucidated yet. To address these points, we developed an in vitro model of oxidative stress by exposing PC12 cells to hydrogen peroxide (H2O2) (150 microM) for 72 h, and we evaluated alpha-syn-mediated protection delivering increasing amounts of alpha-syn (wild type [WT] or mutated) inside cells using the fusion proteins TAT-alpha-syn (WT, A30P, and A53T). We found that nanomolar amounts of TAT-alpha-syn-mediated protected against oxidative stress and other cellular injuries (6-hydroxydopamine and serum deprivation), whereas micromolar amounts of the fusion proteins were intrinsically toxic to cells. The protective effect was independent from the presence of the mutations A30P and A53T, but no protection occurred when cells were challenged with the proteasome inhibitors lactacystin and MG132. We verified that the protection mechanism required the presence of the C-terminal domain of alpha-syn, as nanomolar amounts of the C-terminal truncated fusion protein TAT-alpha-syn (WT[1-97]) failed in preventing H2O2 toxicity. To further characterize the molecular mechanisms at the basis of alpha-syn protection, we investigated the possible involvement of the chaperone protein HSP70 that is widely implicated in neuroprotection. We found that, at nanomolar concentrations, TAT-alpha-syn was able to increase HSP70 protein level, whereas at the micromolar scale, TAT-alpha-syn decreased HSP70 at the protein level. These effects on HSP70 were independent from the presence of alpha-syn pathogenetic mutations but required the alpha-syn C-terminal domain. The implications for alpha-syn-mediated neurotoxicity and for PD pathogenesis and progression are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15345691     DOI: 10.1096/fj.04-1621fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  17 in total

1.  Interaction of α-synuclein and a cell penetrating fusion peptide with higher eukaryotic cell membranes assessed by ¹⁹F NMR.

Authors:  Imola G Zigoneanu; Gary J Pielak
Journal:  Mol Pharm       Date:  2012-03-13       Impact factor: 4.939

2.  Protein aggregation in retinal cells and approaches to cell protection.

Authors:  Irina Surgucheva; Natalia Ninkina; Vladimir L Buchman; Kenneth Grasing; Andrei Surguchov
Journal:  Cell Mol Neurobiol       Date:  2005-09       Impact factor: 5.046

Review 3.  Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease.

Authors:  Seung-Jae Lee
Journal:  J Mol Neurosci       Date:  2007-04-17       Impact factor: 3.444

4.  Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival.

Authors:  Evangelia Emmanouilidou; Katerina Melachroinou; Theodoros Roumeliotis; Spiros D Garbis; Maria Ntzouni; Lukas H Margaritis; Leonidas Stefanis; Kostas Vekrellis
Journal:  J Neurosci       Date:  2010-05-19       Impact factor: 6.167

5.  α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions.

Authors:  Tito Calì; Denis Ottolini; Alessandro Negro; Marisa Brini
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

6.  Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity.

Authors:  Saviana Di Giovanni; Simona Eleuteri; Katerina E Paleologou; Guowei Yin; Markus Zweckstetter; Pierre-Alain Carrupt; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2010-02-11       Impact factor: 5.157

7.  α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity.

Authors:  Huajun Jin; Arthi Kanthasamy; Anamitra Ghosh; Yongjie Yang; Vellareddy Anantharam; Anumantha G Kanthasamy
Journal:  J Neurosci       Date:  2011-02-09       Impact factor: 6.167

8.  DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70.

Authors:  Sara Batelli; Diego Albani; Raffaela Rametta; Letizia Polito; Francesca Prato; Marzia Pesaresi; Alessandro Negro; Gianluigi Forloni
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240

9.  Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats.

Authors:  Zhongwang Yu; Xiaohui Xu; Zhenghua Xiang; Jianfeng Zhou; Zhaohuan Zhang; Chun Hu; Cheng He
Journal:  PLoS One       Date:  2010-04-08       Impact factor: 3.240

10.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.